Physician profile
Kehua Li
NPI 1164488417
$22,487.12
in general payments reported to CMS, 2019-2025
55 companies · $3,477 in 2025
The $3,477 reported for 2025 was more than what 93% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,576 · 2020: $1,878 · 2021: $2,775 · 2022: $4,374 · 2023: $3,676 · 2024: $3,731 · 2025: $3,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,562.98 |
| Education | $321.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,925.94 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,866.06 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,680.88 | 2019-2025 | Siliq, Targretin, Cabtreo |
| Lilly USA, LLC | $1,569.62 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,459.88 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,369.14 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Leo Pharma INC. | $1,260.07 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $1,032.68 | 2019-2025 | |
| Incyte Corporation | $891.82 | 2021-2025 | Opzelura, Opzelura |
| Mayne Pharma Commercial LLC | $864.29 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $809.70 | 2023-2025 | Zoryve |
| Almirall LLC | $775.41 | 2019-2025 | Seysara |
| Ucb, INC. | $624.34 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $539.59 | 2019-2025 | Aklief, Nemluvio, Epsolay |
| Amgen INC. | $531.71 | 2020-2025 | Otezla, Otezla |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kehua Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.